Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R A Engh

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Oncogene|October 26, 2010
The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitroN von Bubnoff, S P Gorantla, R A Engh, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Diarylsulfonamides as selective, non-peptidic thrombin inhibitorsI R Weber, R Neidlein, W von der Saal, et al.
FEBS Letters|December 5, 1994
Structure of leech derived tryptase inhibitor (LDTI-C) in solutionP Mühlhahn, M Czisch, R Morenweiser, et al.
The EMBO Journal|September 1, 1991
The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificityD Musil, D Zucic, D Turk, et al.
Journal of Biomolecular NMR|July 26, 2000
Sequence-specific 1H, 15N, and 13C assignment of the N-terminal domain of the human oncoprotein MDM2 that binds to p53R Stoll, C Renner, P Mühlhahn, et al.
FEBS Letters|August 4, 1997
Quail cystatin: isolation and characterisation of a new member of the cystatin family and its hypothetical interaction with cathepsin BB Gerhartz, R A Engh, R Mentele, et al.
Structure (London, England : 1993)|November 15, 1996
Enzyme flexibility, solvent and 'weak' interactions characterize thrombin-ligand interactions: implications for drug designR A Engh, H Brandstetter, G Sucher, et al.
The EMBO Journal|February 7, 2001
The extracellular human melanoma inhibitory activity (MIA) protein adopts an SH3 domain-like foldR Stoll, C Renner, M Zweckstetter, et al.
Biochemistry|January 10, 2001
Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53R Stoll, C Renner, S Hansen, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Oncogene|October 26, 2010
The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitroN von Bubnoff, S P Gorantla, R A Engh, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Diarylsulfonamides as selective, non-peptidic thrombin inhibitorsI R Weber, R Neidlein, W von der Saal, et al.
FEBS Letters|December 5, 1994
Structure of leech derived tryptase inhibitor (LDTI-C) in solutionP Mühlhahn, M Czisch, R Morenweiser, et al.
The EMBO Journal|September 1, 1991
The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificityD Musil, D Zucic, D Turk, et al.
Journal of Biomolecular NMR|July 26, 2000
Sequence-specific 1H, 15N, and 13C assignment of the N-terminal domain of the human oncoprotein MDM2 that binds to p53R Stoll, C Renner, P Mühlhahn, et al.
FEBS Letters|August 4, 1997
Quail cystatin: isolation and characterisation of a new member of the cystatin family and its hypothetical interaction with cathepsin BB Gerhartz, R A Engh, R Mentele, et al.
Structure (London, England : 1993)|November 15, 1996
Enzyme flexibility, solvent and 'weak' interactions characterize thrombin-ligand interactions: implications for drug designR A Engh, H Brandstetter, G Sucher, et al.
The EMBO Journal|February 7, 2001
The extracellular human melanoma inhibitory activity (MIA) protein adopts an SH3 domain-like foldR Stoll, C Renner, M Zweckstetter, et al.
Biochemistry|January 10, 2001
Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53R Stoll, C Renner, S Hansen, et al.
Pageof 4